PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Santos-Peral, A.* ; Zaucha, M.* ; Nikolova, E.* ; Yaman, E. ; Puzek, B. ; Winheim, E.* ; Goresch, S.* ; Scheck, M.K.* ; Lehmann, L.* ; Dahlstroem, F.* ; Karimzadeh, H.* ; Thorn-Seshold, J.* ; Jia, S.* ; Luppa, F.* ; Pritsch, M.* ; Butt, J.* ; Metz-Zumaran, C.* ; Barba-Spaeth, G.* ; Endres, S. ; Kim-Hellmuth, S. ; Waterboer, T.* ; Krug, A.B.* ; Rothenfußer, S.

Basal T cell activation predicts yellow fever vaccine response independently of cytomegalovirus infection and sex-related immune variations.

Cell Rep. Med. 6:101946 (2025)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
The live-attenuated yellow fever 17D (YF17D) vaccine is a model of acute viral infection that induces long-lasting protective immunity. Among immunocompetent adults, responses to YF17D vary significantly. To understand the sources of this variability, we investigate the influence of sex, age, human leukocyte antigen (HLA) type, and 20 prior infections on basal immune parameters and the cellular and antibody response to YF17D in 250 healthy young individuals. Multivariate regression found that sex and cytomegalovirus (CMV) infection significantly contribute to baseline immune variation but do not affect vaccine responses except for reduced YF17D-specific CD8+ frequencies in CMV-infected males. However, the abundance at baseline of non-specific cytokine-expressing T helper cells in circulation is associated with stronger vaccine responses, a state that smoking favors. Additionally, an elevated baseline level of interferon-stimulated CXCL10 is linked to poorer vaccination outcomes. Altogether, YF17D reactivity is conditioned by the baseline immune status independent of sex and CMV-related variations.
Impact Factor
Scopus SNIP
Altmetric
10.600
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Yf17d ; Adaptive Immunity ; Flavivirus ; Human Immune Variability ; Immunogenicity ; Live Vaccine ; Vaccine Response ; Yellow Fever Vaccine; Immunogenicity; Impact; Safety; Seropositivity; Cd4(+); Virus; Cmv
Sprache englisch
Veröffentlichungsjahr 2025
HGF-Berichtsjahr 2025
ISSN (print) / ISBN 2666-3791
e-ISSN 2666-3791
Zeitschrift Cell Reports Medicine
Quellenangaben Band: 6, Heft: 2, Seiten: , Artikelnummer: 101946 Supplement: ,
Verlag Cell Press
Verlagsort 50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Unit for Clinical Pharmacology (KKG-EKLiP)
Institute of Translational Genomics (ITG)
POF Topic(s) 30203 - Molecular Targets and Therapies
30205 - Bioengineering and Digital Health
Forschungsfeld(er) Immune Response and Infection
Genetics and Epidemiology
PSP-Element(e) G-522100-001
G-506700-001
Förderungen DFG
French National Research Agency (ANR)
FlavImmunity, a combined grant of the German Research Foundation (DFG)
Yellow4FLAVI project - European Union
IMed consortium of the German Helmholtz Societies
Einheit fur Klinische Pharmakologie (EKLIP), Helmholtz Zentrum Munchen, Neuherberg, Germany
Friedrich Baur Foundation (FBS)
Metiphys fellowship of the Medical Faculty of the LMU Munich
FoFoLe Program of the Medical Faculty of the LMU Munich
Doctoral program iTarget 2.0
International doctoral program "iTarget: Immunotargeting of cancer" - Elite Network of Bavaria
European Union
DOI 10.1016/j.xcrm.2025.101946
WOS ID 001434392200001
Scopus ID 85217895844
PubMed ID 39938525
Erfassungsdatum 2025-04-09
[➜Korrektur melden]